NR1H4 and metabolic dysfunction-associated steatohepatitis: The complex mechanism of BA action in the development of NAFLD/NASH is controlled primarily by the farnesoid X receptor (FXR), activated by primary BAs, and Takeda G protein-coupled receptors 5 (TGR5), activated by secondary BAs [81].